Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series
Author:
Funder
Fonds Wetenschappelijk Onderzoek
Universitaire Ziekenhuizen Leuven
Publisher
Springer Science and Business Media LLC
Subject
Pulmonary and Respiratory Medicine
Link
http://link.springer.com/content/pdf/10.1186/s12890-016-0308-z.pdf
Reference21 articles.
1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.
2. National Institute for Health and Care Excellence: clinical guidelines;National Clinical Guideline Centre (UK),2013
3. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, CAPACITY Study Group, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–9.
4. King Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, ASCEND Study Group, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.
5. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, INPULSIS Trial Investigators, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.
Cited by 60 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Delayed healing of rectal mucosa after endoscopic submucosal dissection (ESD) with nintedanib use;BMJ Case Reports;2023-12
2. Lung Transplantation: Selection of Candidates;OBM Transplantation;2023-10-11
3. Effect of antifibrotic agents on postoperative complications after lung transplantation for idiopathic pulmonary fibrosis;Respirology;2023-10-03
4. French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis – 2021 update. Full-length version;Respiratory Medicine and Research;2023-06
5. A Narrative Review of Real-World Data on the Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis;Advances in Therapy;2023-03-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3